It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mitochondrial diseases impair oxidative phosphorylation and ATP production, while effective treatment is still lacking. Defective complex III is associated with a highly variable clinical spectrum. We show that pyocyanin, a bacterial redox cycler, can replace the redox functions of complex III, acting as an electron shunt. Sub-μM pyocyanin was harmless, restored respiration and increased ATP production in fibroblasts from five patients harboring pathogenic mutations in TTC19, BCS1L or LYRM7, involved in assembly/stabilization of complex III. Pyocyanin normalized the mitochondrial membrane potential, and mildly increased ROS production and biogenesis. These in vitro effects were confirmed in both DrosophilaTTC19KO and in Danio rerioTTC19KD, as administration of low concentrations of pyocyanin significantly ameliorated movement proficiency. Importantly, daily administration of pyocyanin for two months was not toxic in control mice. Our results point to utilization of redox cyclers for therapy of complex III disorders.
Mitochondrial diseases, including those caused by defects in complex III of the respiratory chain, lack curative treatments. Here the authors report that the small molecule pyocyanin has beneficial effects in cells derived from patients with complex III-deficiency as well as in fly and zebrafish genetic models with reduced complex III activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 University of Padova, Department of Biology, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); University of California, Department of Molecular and Cell Biology, Berkeley, USA (GRID:grid.47840.3f) (ISNI:0000 0001 2181 7878)
2 University of Padova, Department of Biology, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
3 CNR Institute of Neuroscience, Padova, Italy (GRID:grid.418879.b) (ISNI:0000 0004 1758 9800); University of Padova, Department of Biomedical Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
4 Fondazione IRCCS Istituto Neurologico Carlo Besta, Unit of Medical Genetics and Neurogenetics, Milano, Italy (GRID:grid.417894.7) (ISNI:0000 0001 0707 5492); University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy (GRID:grid.4708.b) (ISNI:0000 0004 1757 2822)
5 University of Padova, Department of Neurosciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); Venetian Institute of Molecular Medicine, Padova, Italy (GRID:grid.428736.c)
6 University of Padova, Department of Biomedical Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
7 University of Padova, Department of Biology, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470); CNR Institute of Neuroscience, Padova, Italy (GRID:grid.418879.b) (ISNI:0000 0004 1758 9800)